CD79B
B-cell antigen receptor complex-associated protein beta chain
As of the edition of 20 October 2026, CD79B (B-cell antigen receptor complex-associated protein beta chain, UniProt P40259) has 4 drugs tested at it and 4 companies on the list, 1 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P40259
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 6
- Disease areas
- Blood and lymph; Cancer; Immune system; Chemically induced; Heart and blood vessels; Infections; Injuries; Skin and connective tissue
- Registered trials of its drugs
- 88
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Polatuzumab vedotin | Marketed | Phase 3 | Ends 2031 |
| JNJ-80948543 | Active | Phase 1 | none listed |
| MGD-010 | Stopped | Phase 2 | none listed |
| DCDS0780A | Went quiet | Phase 1 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 1 |
| Engaged | 2 |
| Total on the list | 4 |
The other 2 companies at CD79B
In the product4 companies in all; 2 are not named here, and no score is.
See the 4 companies at CD79B, ranked, with the facts behind eachRequest access. Nothing is shown until you do.